BioCentury
ARTICLE | Clinical News

FDA approves BMS's Sprycel for pediatric ALL

January 4, 2019 1:46 AM UTC

FDA approved an sNDA from Bristol-Myers Squibb Co. (NYSE:BMY) to expand the label of Sprycel dasatinib to include treatment of pediatric patients ages one and older with Philadelphia chromosome-positive (Ph+) acute lymphoblastic leukemia (ALL).

The drug is already approved for the indication in adults and to treat Ph+ chronic myelogenous leukemia (CML) in patients ages one and older...

BCIQ Company Profiles

Bristol Myers Squibb Co.